Zeta's ATRX recombinant monoclonal antibody is helpful for glioma classification (along with IDH1/p53, and Ki67). Additionally, loss of ATRX in pancreatic endocrine tumors is associated with chromosomal instability. Visit https://lnkd.in/eipnJuTv for more information.
Zeta Corporation - Precision IVD Antibodies for Anatomic Pathology
Biotechnology Research
Arcadia, CA 2,022 followers
ISO 13485: 2016 certified company offering target-validated and characterized monoclonal antibodies for Pathology/IHC.
About us
Zeta Corporation is an ISO 13485:2016 and FDA registered biomedical company that manufactures and distributes IVD antibodies for Pathology/IHC. We provide the highest quality of antibodies to help pathologists diagnose human tumors and diseases. Zeta antibodies are carefully curated to produce reproducible results on formalin-fixed, paraffin-embedded (FFPE) sections manually or using commercially available automated equipment. Zeta utilizes its collective knowledge of over 75 years to validate and standardize every antibody individually for immunohistochemistry (IHC) application. Zeta designs and develops tumor-specific biomarkers using cutting-edge technology to uniquely select the immunogens for our famed RAbMono™ (Rabbit Monoclonal) and MonoMAb™ (Monospecific monoclonal antibodies). Zeta’s MonoMAb™ and RAbMono™ Antibodies are produced through hybridoma and recombinant technologies. MonoMAb™: The clones are first screened by ELISA and gel electrophoresis to determine their specificity. The selected antibodies are further screened by staining FFPE sections. Only those antibodies that worked on FFPE sections are selected for further protein array analysis to select the highly specific clones for IHC. RAbMono™: Rabbit monoclonal primary antibodies are designed and developed by Zeta’s accomplished scientists and validated to perform with high sensitivity and specificity. It is our commitment to produce and release several primary antibodies for the routine and unique targets. We are proud of our commitment to producing highly specific, target-validated, and characterized IVD primary biomarkers to aid pathologists in the differential diagnosis of various tumors. Zeta Corporation sells the products directly in the US and distributes them to over 50 different countries globally through our trusted partners. Zeta offers CE-IVD labeled products with European regulatory compliance and encourages distributors to register the products in the individual territories.
- Website
-
https://www.zeta-corp.com/
External link for Zeta Corporation - Precision IVD Antibodies for Anatomic Pathology
- Industry
- Biotechnology Research
- Company size
- 2-10 employees
- Headquarters
- Arcadia, CA
- Type
- Privately Held
- Founded
- 2003
- Specialties
- immunohistochemistry, medical device, GMP certified, ISO certified, antibodies, IHC, Histology, Pathology, biotechnology, monoclonal antibodies, monospecific, ISO 13485, immunopathology, FFPE, paraffin tissue, FDA Registered, NordiQC Registered, NordiQC Participant, ISO 13485: 2016, diagnostics, and biomedical
Locations
-
Primary
Get directions
65 N 1st Ave
#202C
Arcadia, CA 91006, US
Employees at Zeta Corporation - Precision IVD Antibodies for Anatomic Pathology
Updates
-
Zeta Corporation is a leader in recombinant rabbit and mouse monoclonal antibodies for immunohistochemistry. Created by a pathologist for pathologists, we have one of the largest catalogs of diagnostically-relevant antibodies for tumor and tissue identification and classification. If you don't see what you need in our catalog or website, send a note to [email protected]. We are launching another 12 antibodies this fall and have access to extensive additional content. We are excited to launch our latest catalog including our newest antibodies. The electronic version of Zeta's updated catalog is launched! https://lnkd.in/gJ_EQbhX
-
-
Zeta Corporation - Precision IVD Antibodies for Anatomic Pathology reposted this
Chief Commercial Officer - Commercial Strategies - Decision Maker - Communicator - Growth Generator - Client Centric - Marketeer - Sales Driver - Team Builder
https://lnkd.in/e2cU9EFz 2BScientific Ltd. are offering our GenomeMe, Zeta Corporation - Precision IVD Antibodies for Anatomic Pathology, and Optibodies™ from Nordic Biosite, IVD ranges at a 15% discount. Contact mathew green our Specialist Inside Sales Manager for more information. #ivd #2bscientific #hereforyou
-
-
Zeta Corporation - Precision IVD Antibodies for Anatomic Pathology reposted this
Learn more about Zeta's recombinant mouse monoclonal IVD antibody to NKX3.1 as we focus on this important prostatic tumor marker.
-
-
Zeta Corporation - Precision IVD Antibodies for Anatomic Pathology reposted this
Histology Equipment Market Size And Forecast Histology Equipment Market size is expected to develop revenue and exponential market growth at a remarkable CAGR during the forecast period from 2024–2031. The comprehensive report of the Histology Equipment Market will analyse data changes and their impact on the market at the global level. It also analyses the overall growth of companies in the market and their abilities to manage and control profit levels, which is highly important to any investor wishing to open and expand a company within the same market. ➢𝐓𝐨𝐩 𝐊𝐞𝐲 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 𝐦𝐞𝐧𝐭𝐢𝐨𝐧𝐞𝐝 𝐚𝐬 𝐛𝐞𝐥𝐨𝐰: ➢ ➢ StatLab ➢ Avantika Patil ➢ Electron Microscopy Sciences ➢ Azer Scientific ➢ Mopec ➢ Boekel Scientific ➢ Mercedes Scientific ➢ Island Group Enterprises ➢ Versiti Blood Research Institute ➢ NCI Inc., a Thomas Scientific, LLC Company➢ HistologyEquipment.com ➢ HistologyEquipment.com ➢ Histology Equipment Services Ltd ➢ Histology Equipment Services Ltd. ➢ Medical Equipment Source ➢ StatLab ➢ Avantika Patil ➢ Electron Microscopy Sciences ➢ Azer Scientific ➢ Mopec ➢ CellPath, a StatLab Company ➢ Zeta Corporation - Precision IVD Antibodies for Anatomic Pathology #data #sales #marketresearch #research #entrepreneur #businessstrategy #technology #data #sales #datacollection #salesfunnel #contentmarketing #bhfyp #size #forecast # #Share #Scope #Opportunities #Analysis #HistologyEquipmentMarket
-
-
The predominantly nuclear residing transcription factor GATA-3 exerts critical roles in the CD4 T cell compartment of adaptive immunity as well as in the development and disease progression of various neoplasms including breast carcinoma. The GATA-3 Zeta-Antibody clone ZR358 readily assesses the GATA-3 antigen in tissue sections of neoplasms including breast carcinoma and urothelial carcinoma.